INTRODUCTION {#s1}
============

Mycoplasma genitalium is a fastidious bacterium in the class *Mollicutes*. Its minute 580-kb genome is the smallest known among prokaryotes capable of self-replication ([@B1], [@B2]). M. genitalium was first cultured in 1981 using urethral specimens from men with nongonococcal urethritis (NGU) ([@B3]). Slow growth *in vitro* and burdensome culture requirements have precluded routine diagnosis using this method ([@B4]). Nucleic amplification assay tests (NAATs) based on PCR and transcription-mediated amplification (TMA) chemistries have been necessary for the study of associations between infection in humans and disease ([@B5][@B6][@B9]). Since the availability of such molecular assays, the organism has been associated with many disease syndromes, such as urethritis in men and cervicitis and adverse reproductive sequelae such as endometritis and pelvic inflammatory disease in women. In addition to the cervix, vagina, and male urethra, M. genitalium is also found in the oropharynx and rectum ([@B10][@B11][@B20]). An association of M. genitalium infection with risk for HIV infection has been reported also ([@B21]). Increasing the concerns about treatment of the syndromes associated with M. genitalium are the reports of rising rates of resistance to azithromycin and moxifloxacin ([@B22], [@B23]), the primary agents used to treat these conditions. The overall importance of M. genitalium as a sexually transmitted pathogen has been comprehensively reviewed ([@B24]).

The development of the Aptima Mycoplasma genitalium (AMG) assay, an *in vitro* diagnostic (IVD) transcription-mediated amplification (TMA) assay that targets the 16S RNA of M. genitalium, has led to its experimental use to study the epidemiology and clinical outcomes associated with infection with the organism, as well as to a comparison with other molecular amplification assays ([@B15], [@B16], [@B25][@B26][@B30]). The assay has been used with sequencing to demonstrate high levels of macrolide antibiotic resistance in M. genitalium infections originating in the United States ([@B31]). Following receipt of the Conformité Européene (CE) mark from the European Union ([@B32], [@B33]), the AMG assay was clinically validated for detection of M. genitalium in urogenital specimens collected from subjects enrolled in a prospective, multicenter study encompassing multiple regions of the United States. The manuscript reports a summary of the U.S. study results.

MATERIALS AND METHODS {#s2}
=====================

Study design and ethics approval. {#s2.1}
---------------------------------

This cross-sectional study was conducted in accordance with the ethical principles derived from the Declaration of Helsinki and Belmont Report and in compliance with the U.S. Food and Drug Administration (FDA) and Good Clinical Practice Guidelines (cGCP) set forth by the International Conference on Harmonization (ICH-E6). The study protocol (A10109-MGENPS-CSP-01) was approved by the local institutional review board at every site. Written informed consent was obtained from each subject at the time of enrollment, prior to specimen collection. Participants were compensated for study participation.

Study population. {#s2.2}
-----------------

Sexually active female and male subjects of ≥14 years of age with (symptomatic) or without (asymptomatic) symptoms of sexually transmitted infections (STIs) (e.g., abnormal discharge, genital itching, pain/discomfort during sexual intercourse or urination, or pain/discomfort in groin or lower belly) were eligible for enrollment. Subjects were enrolled at 21 U.S. sites (clinical research centers and emergency medicine, family planning, public health, STI, family medicine/obstetric-gynecologic \[OB-GYN\] facilities) between July 2017 and April 2018. Exclusion criteria included antibiotic treatment (i.e., with macrolides, fluoroquinolones, tetracyclines, or clindamycin) within 21 days of enrollment or previous enrollment in this study.

Sample collection. {#s2.3}
------------------

Four specimens were collected in the clinic from each female subject in the following order: one self-collected first-catch urine specimen, one self-collected vaginal swab specimen, one clinician-collected vaginal swab specimen, and one clinician-collected endocervical swab specimen. Three specimens were collected in the clinic from each male subject in the following order: one self-collected penile meatal swab specimen, one clinician-collected urethral swab specimen, and one self-collected first-catch urine specimen. Vaginal and penile meatal specimens were collected using Aptima multitest swabs and placed in Aptima tubes containing specimen transfer medium (STM). Urethral and endocervical specimens were collected using an Aptima unisex swab and placed in Aptima tubes containing STM. First-catch urine specimens (i.e., approximately 20 to 30 ml of the initial urine stream collected in a urine collection cup free of any preservatives) were processed for testing using an Aptima urine specimen collection kit and placed in Aptima tubes containing urine transport medium (UTM).

TMA and specimen testing. {#s2.4}
-------------------------

The design, format, and comparative analytical performance of the AMG transcription-mediated amplification (TMA) assays and three alternate (Alt) TMA assays used for the composite reference standard have been described previously ([@B34]). All specimens were tested first with the AMG assay on an automated Panther system in one of three U.S. laboratories before being transported to Hologic for reference testing. Reference testing was performed using three research-use-validated alternate TMA assays developed by Hologic to capture, amplify, and detect unique regions of the 16S rRNA (Alt TMA assay-1) or 23S rRNA (Alt TMA assay-2 and Alt TMA assay-3) of M. genitalium; the Alt TMA assay-1 detected a different region of the 16S rRNA than the AMG assay. All three Alt TMA assays have similar analytical and clinical sensitivities ([@B34]). Alt TMA assays were performed on a Panther system (Alt TMA assays-1 and -2) or a manual direct tube sampling (DTS) system (Alt TMA-3) using validated laboratory-developed assay software. Each specimen was tested using Alt TMA assays -1 and -2; if the results of the two tests were discordant, the result from Alt TMA assay-3 testing was used as a tiebreaker. If two Alt TMA assay results were positive, the reference result was classified positive; if two Alt TMA results were negative, the reference result was negative ([Table 1](#T1){ref-type="table"}). Operators performing Alt TMA assays were blinded to AMG test results and all patient identifying information.

###### 

Algorithm for establishing patient infected status using alternate TMA assay consensus results

  Reference specimen result[^*a*^](#T1F1){ref-type="table-fn"}   Patient infected status                     
  -------------------------------------------------------------- ------------------------- ----------------- ----------
  Positive                                                       Positive                  NA                Positive
  Negative                                                       Invalid/missing           Unknown           
  Negative                                                       Positive                  Positive          
  Negative                                                       Negative                  Negative          
  Invalid/missing                                                Invalid/missing           Unknown           
  Invalid/missing                                                Positive                  Positive          
  Invalid/missing                                                Negative                  Unknown           
  Negative                                                       Positive                  Invalid/missing   Unknown
  Positive                                                       Positive                  Positive          
  Positive                                                       Negative                  Negative          
  Negative                                                       NA                        Negative          
  Invalid/missing                                                Invalid/missing           Unknown           
  Invalid/missing                                                Positive                  Unknown           
  Invalid/missing                                                Negative                  Negative          
  Invalid/missing                                                Positive                  Invalid/missing   Unknown
  Positive                                                       Positive                  Positive          
  Positive                                                       Negative                  Unknown           
  Negative                                                       Invalid/missing           Unknown           
  Negative                                                       Positive                  Unknown           
  Negative                                                       Negative                  Negative          
  Invalid/missing                                                NA                        Unknown           

The reference specimen is the urethral swab sample for male subjects and the self-collected vaginal swab sample for female subjects. NA, not applicable.

Alt TMA, alternate transcription-mediated amplification.

Statistical methods. {#s2.5}
--------------------

Prevalence (based on reference test result and patient infected status \[PIS\]), sensitivity, specificity, positive predictive value, and negative predictive value were calculated according to standard equations ([@B35]). Confidence intervals (CIs) for sensitivity and specificity were calculated using the score method. The confidence intervals for positive and negative predictive values were calculated using the exact method. Samples with inconclusive reference results and samples with invalid or missing investigational assay results were excluded from the analyses. The positive likelihood ratio (PLR) was calculated as sensitivity/(1 − specificity), and negative likelihood (NLR) was calculated as (1 − sensitivity)/specificity. Analyses were performed with SAS software (version 9.4; SAS Institute, Inc., Cary, NC).

PIS. {#s2.6}
----

To determine the clinical performance of the investigational assay in the assessed specimen types, Aptima TMA results were assessed relative to the patient infected status (PIS). The PIS was based on reference (composite Alt TMA assay) results from testing of the urethral swab sample for male subjects and of the patient-collected vaginal swab sample for female subjects; based on prior studies, vaginal swab and urethral samples are the most sensitive specimen types for the detection of M. genitalium ([@B25], [@B36], [@B37]). [Table 1](#T1){ref-type="table"} shows the algorithm for establishing the PIS. Unless otherwise specified, for each specimen type, assay performance for the detection of M. genitalium was calculated relative to the PIS.

RESULTS {#s3}
=======

Study design and subject accountability. {#s3.1}
----------------------------------------

[Figure 1](#F1){ref-type="fig"} shows the patient accountability log, as well as the final numbers of evaluable samples for each specimen type. There were 3,393 subjects enrolled in the study, including 1,789 females and 1,604 males. Of these, 32 subjects were withdrawn for various reasons, including ineligibility or self-termination of participation. An additional 61 subjects with insufficient test results available for establishing a PIS were excluded, leaving 3,300 subjects (1,737 females and 1,563 males) evaluable for analysis. A total of 11,556 specimens were collected and analyzed using four female specimen types (*n* = 6,880) and three male specimen types (*n* = 4,676).

![Overall study design and subject accountability. Subjects were not evaluable for the analysis versus PIS if they had an unknown PIS. Specimens with missing or invalid Aptima results were excluded from all analyses.](JCM.01125-19-f0001){#F1}

Demographic characteristics of enrolled subjects for sex, age, and race/ethnicity, as well as symptom status and M. genitalium prevalence for each group, are shown in [Table 2](#T2){ref-type="table"}. The majority of subjects were between 18 and 40 years of age (83.7% female; 70.1% male), Black (∼61% for both sexes), non-Hispanic (∼77% for both sexes), and from southeast or southwest clinical centers (∼74% for both sexes). For females, 60.6% were symptomatic; 55.4% of males were symptomatic. For females, M. genitalium prevalence was 11.6% and 7.9% among symptomatic and asymptomatic subjects, respectively; for males, M. genitalium prevalence was 12.0% and 8.8% among symptomatic and asymptomatic subjects, respectively. The highest prevalence of infection was in young adults of both sexes aged 18 to 20 years (female, 26.2%; male, 15.1%).

###### 

Prevalence of M. genitalium urogenital infection by subject demographic status and geographic region

  Category                                                    No. of specimens   M. genitalium prevalence                                   
  ----------------------------------------------------------- ------------------ -------------------------- ------------------- ----------- -------------------
  Subject age (yr)                                                                                                                          
      15--17                                                  4                  0/3                        0 (0.0--56.1)       0/1         0 (0.0--79.3)
      18--20                                                  242                39/149                     26.2 (19.8--33.8)   14/93       15.1 (9.2--23.7)
      21--30                                                  1,379              94/805                     11.7 (9.6--14.1)    81/574      14.1 (11.5--17.2)
      31--40                                                  929                36/500                     7.2 (5.2--9.8)      53/429      12.4 (9.6--15.8)
      41--50                                                  345                6/157                      3.8 (1.8--8.1)      11/188      5.9 (3.3--10.2)
      51--60                                                  298                1/94                       1.1 (0.2--5.8)      5/204       2.5 (1.1--5.6)
      61--70                                                  90                 0/25                       0 (0.0--13.3)       1/65        1.5 (0.3--8.2)
      71--82                                                  13                 0/4                        0 (0.0--49.0)       0/9         0 (0.0--29.9)
      All females (15--74)                                    1,737              176/1,737                  10.1 (8.8--11.6)                
      All males (16--82)                                      1,563                                                             165/1,563   10.6 (9.1--12.2)
  Symptom status[^*a*^](#T2F1){ref-type="table-fn"}                                                                                         
      Symptomatic                                             1,919              122/1,053                  11.6 (9.8--13.7)    104/866     12.0 (10.0--14.3)
      Asymptomatic                                            1,381              54/684                     7.9 (6.1--10.2)     61/697      8.8 (6.9--11.1)
  Subject race/ethnicity[^*b*^](#T2F2){ref-type="table-fn"}                                                                                 
      Asian                                                   47                 5/29                       17.2 (7.6--34.5)    0/18        0 (0.0--17.6)
      Black                                                   2,025              127/1,059                  12.0 (10.2--14.1)   125/966     12.9 (11.0--15.2)
      White                                                   1,131              40/591                     6.8 (5.0--9.1)      37/540      6.9 (5.0--9.3)
      Unknown/other race                                      146                6/79                       7.6 (3.5--15.6)     6/67        9.0 (4.2--18.2)
      Hispanic                                                720                23/381                     6.0 (4.1--8.9)      23/339      6.8 (4.6--10.0)
      Non-Hispanic                                            2,556              151/1,347                  11.2 (9.6--13.0)    140/1,209   11.6 (9.9--13.5)
      Unknown ethnicity                                       24                 2/9                        22.2 (6.3--54.7)    2/15        13.3 (3.7--37.9)
  U.S. geographic area[^*c*^](#T2F3){ref-type="table-fn"}                                                                                   
      Mid-Atlantic                                            260                16/142                     11.3 (7.1--17.5)    13/118      11.0 (6.6--17.9)
      Midwest                                                 288                23/190                     12.1 (8.2--17.5)    14/98       14.3 (8.7--22.6)
      Northeast                                               225                13/106                     12.3 (7.3--19.9)    11/119      9.2 (5.2--15.8)
      Northwest                                               65                 0/12                       0 (0.0--24.2)       3/53        5.7 (1.9--15.4)
      Southeast                                               1,424              72/703                     10.2 (8.2--12.7)    84/721      11.7 (9.5--14.2)
      Southwest                                               1,038              52/584                     8.9 (6.9--11.5)     40/454      8.8 (6.5--11.8)

Symptom status was determined based on subject-reported symptoms.

Subjects could report multiple responses.

Mid-Atlantic: Maryland, North Carolina, and Washington DC; Midwest: Indiana, Michigan, Nebraska, and Ohio (2 sites); Northeast: Connecticut and New Jersey; Northwest: Washington; Southeast: Alabama, Georgia, Florida (3 sites), and Louisiana; Southwest: California (2 sites) and Texas (2 sites).

Prevalence and clinical performance. {#s3.2}
------------------------------------

The M. genitalium prevalence and the clinical performance of the investigational assay for the detection of M. genitalium are shown in [Table 3](#T3){ref-type="table"} for each specimen type overall and by symptom status. In females, prevalence was lowest (7.9%) in endocervical and urine samples from asymptomatic subjects and highest (11.6%) in urine samples and patient-collected vaginal specimens from symptomatic subjects. In males, prevalence was lowest in urine specimens (8.7%) from asymptomatic subjects and highest (12%) in urethral swab and urine specimens from symptomatic subjects. The overall prevalence of M. genitalium was similar for clinician-collected vaginal swabs, patient-collected vaginal swab, endocervical swab, and female urine specimens (10.2, 10.2, 10.1, and 10.2%, respectively) and for urethral swab, penile-meatal swab, and male urine specimens (10.6, 10.6, and 10.5%, respectively).

###### 

Clinical performance characteristics of the Aptima Mycoplasma genitalium assay in urogenital specimens from female and male subjects

  Specimen type and subject symptom status[^*a*^](#T3F1){ref-type="table-fn"}   No. of specimens   Prevalence (%)   Sensitivity (% \[95% CI\])   Specificity (% 95% CI)   PPV (95% CI)[^*b*^](#T3F2){ref-type="table-fn"}   NPV (95% CI)[^*c*^](#T3F3){ref-type="table-fn"}   PLR (95% CI)[^*d*^](#T3F4){ref-type="table-fn"}   NLR (95% CI)[^*e*^](#T3F5){ref-type="table-fn"}
  ----------------------------------------------------------------------------- ------------------ ---------------- ---------------------------- ------------------------ ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- -------------------------------------------------
  Clinician-collected vaginal swab                                                                                                                                                                                                                                                                                              
      Sym                                                                       1,040              11.5             93.3 (87.4--96.6)            97.6 (96.4--98.4)        83.6 (77.3--88.8)                                 99.1 (98.3--99.6)                                 39.0 (26.2--60.8)                                 0.07 (0.03--0.13)
      Asym                                                                      669                8.1              88.9 (77.8--94.8)            98.7 (97.5--99.3)        85.7 (75.8--92.9)                                 99.0 (98.0--99.6)                                 68.3 (35.6--148.8)                                0.11 (0.04--0.23)
      Overall                                                                   1,709              10.2             92.0 (86.9--95.1)            98.0 (97.2--98.6)        84.2 (79.1--88.6)                                 99.1 (98.5--99.5)                                 47.0 (33.4--68.8)                                 0.08 (0.05--0.13)
  Patient-collected vaginal swab                                                                                                                                                                                                                                                                                                
      Sym                                                                       1,047              11.6             100 (96.9--100)              98.1 (96.9--98.8)        87.1 (81.1--91.9)                                 100 (99.6--100)                                   51.4 (32.7--86.5)                                 0.00 (0.00--0.03)
      Asym                                                                      677                8.0              96.3 (87.5--99.0)            99.0 (97.9--99.6)        89.7 (80.4--95.7)                                 99.7 (98.9--100)                                  100 (47.4--258.2)                                 0.04 (0.00--0.13)
      Overall                                                                   1,724              10.2             98.9 (95.9--99.7)            98.5 (97.7--99.0)        87.8 (83.1--91.7)                                 99.9 (99.5--100)                                  63.8 (43.4--97.9)                                 0.01 (0.00--0.04)
  Endocervical swab                                                                                                                                                                                                                                                                                                             
      Sym                                                                       1,046              11.5             84.2 (76.6--89.6)            98.2 (97.1--98.9)        85.6 (79.1--90.8)                                 98.0 (97.0--98.7)                                 45.9 (29.1--76.4)                                 0.16 (0.1--0.24)
      Asym                                                                      669                7.9              75.5 (62.4--85.1)            98.5 (97.2--99.2)        81.6 (70.3--90.2)                                 97.9 (96.8--98.8)                                 51.7 (27.5--107.2)                                0.25 (0.14--0.39)
      Overall                                                                   1,715              10.1             81.5 (75.1--86.6)            98.3 (97.5--98.8)        84.4 (78.9--89.1)                                 97.9 (97.2--98.5)                                 48.3 (33.3--72.7)                                 0.19 (0.13--0.25)
  Female urine                                                                                                                                                                                                                                                                                                                  
      Sym                                                                       1,051              11.6             79.5 (71.5--85.7)            98.4 (97.4--99.0)        86.6 (80.0--91.8)                                 97.3 (96.3--98.2)                                 49.2 (30.4--85.7)                                 0.21 (0.14--0.29)
      Asym                                                                      682                7.9              74.1 (61.1--83.9)            99.8 (99.1--100)         97.6 (88.7--99.9)                                 97.8 (96.7--98.7)                                 465.2 (91.6--15,195.2)                            0.26 (0.15--0.4)
      Overall                                                                   1,733              10.2             77.8 (71.1--83.3)            99.0 (98.3--99.4)        89.5 (84.3--93.6)                                 97.5 (96.8--98.2)                                 75.8 (47.5--128.6)                                0.22 (0.17--0.29)
  Male urethral swab                                                                                                                                                                                                                                                                                                            
      Sym                                                                       866                12.0             98.1 (93.3--99.5)            99.9 (99.3--100)         99.0 (94.9--100)                                  99.7 (99.1--100)                                  747.4 (136.8--27,947.9)                           0.02 (0.00--0.07)
      Asym                                                                      697                8.8              98.4 (91.3--99.7)            99.2 (98.2--99.7)        92.3 (84.0--97.3)                                 99.8 (99.2--100)                                  125.1 (54.7--369.0)                               0.02 (0.00--0.09)
      Overall                                                                   1,563              10.6             98.2 (94.8--99.4)            99.6 (99.1--99.8)        96.4 (92.7--98.6)                                 99.8 (99.4--100)                                  228.8 (106.8--605.2)                              0.02 (0.00--0.05)
  Penile meatal swab                                                                                                                                                                                                                                                                                                            
      Sym                                                                       865                11.9             89.3 (81.9--93.9)            97.8 (96.5--98.6)        84.4 (77.5--90.0)                                 98.5 (97.6--99.2)                                 40.0 (25.4--66.7)                                 0.11 (0.06--0.19)
      Asym                                                                      689                8.9              86.9 (76.2--93.2)            97.9 (96.5--98.8)        80.3 (70.8--88.1)                                 98.7 (97.7--99.4)                                 42.0 (25.0--75.9)                                 0.13 (0.06--0.24)
      Overall                                                                   1,554              10.6             88.4 (82.6--92.5)            97.8 (96.9--98.5)        82.9 (77.4--87.6)                                 98.6 (97.9--99.1)                                 40.9 (29.0--59.8)                                 0.12 (0.07--0.18)
  Male urine                                                                                                                                                                                                                                                                                                                    
      Sym                                                                       866                12.0             89.4 (82.0--94.0)            99.1 (98.1--99.6)        93.0 (86.9--96.9)                                 98.6 (97.6--99.3)                                 97.3 (48.5--228.4)                                0.11 (0.06--0.18)
      Asym                                                                      693                8.7              93.3 (84.1--97.4)            99.7 (98.9--99.9)        96.6 (89.0--99.5)                                 99.4 (98.5--99.8)                                 295.4 (85.6--2,229.8)                             0.07 (0.02--0.16)
      Overall                                                                   1,559              10.5             90.9 (85.5--94.4)            99.4 (98.8--99.7)        94.3 (90.0--97.2)                                 98.9 (98.3--99.4)                                 140.8 (76.2--294.7)                               0.09 (0.05--0.15)

Symptom status was determined based on subject-reported symptoms. Asym, asymptomatic; Sym, symptomatic.

PPV, positive predictive value.

NPV, negative predictive value.

PLR, positive likelihood ratio.

NLR, negative likelihood ratio.

Overall sensitivity of the investigational test for detection of M. genitalium-infected subjects was ≥90% for clinician- and patient-collected vaginal and male urethral swab specimens and male urine specimens, 88.4% for penile-meatal swab specimens, 81.5% for endocervical specimens, and 77.8% for female urine specimens. Overall specificity was ≥97.8% for all specimen types. The combination of investigational and reference assay M. genitalium results for all subjects with a conclusive PIS status and valid AMG assay results are shown in Tables S1 and S2 in the supplemental material for female and male urogenital specimens, respectively. Sensitivity and specificity estimates were similar in asymptomatic and symptomatic subjects for each specimen type. Assay performance was similar among races and ethnicities for each specimen type (Tables S3 and S4).

In the absence of results from FDA-approved assays for M. genitalium detection for performance comparison, positive (PLR) and negative (NLR) likelihood ratios were also calculated. By symptom status, estimates of the PLR in female specimen types ranged from 39.0 (95% CI, 26.2 to 60.8) for clinician-collected vaginal swab specimens from symptomatic subjects to 465.2 (95% CI, 91.6 to 15,195.2) for female urine specimens from asymptomatic subjects. For male specimens, PLR estimates ranged from 40.0 (95% CI, 25.4 to 66.7) for penile meatal swab specimens from symptomatic subjects to 747.4 (95% CI, 136.8 to 27,947.9) for urethral swab specimens from symptomatic subjects. For all specimen types, NLR ratios were less than 0.26. Together, these results demonstrated highly relevant and statistically significant increases in knowledge based on positive and negative AMG assay results in all specimen types.

To investigate the effect of the clinical specimen matrix on investigational assay performance for specimens other than the male urethral swab and self-collected vaginal swab, a comparison of AMG assay and Alt TMA assay results within the same specimen type was performed ([Table 4](#T4){ref-type="table"}). Infected specimen status was determined for these analyses using the same general rules as for the PIS, except that the infected status was determined based on the composite Alt TMA reference result for that specimen instead of in comparison to the patient-collected vaginal swab specimen (for women) or the urethral swab specimen (for men). Positive percent agreement (PPA) using the specimen infected status standard was \>95% for all specimen types except female urine, for which the PPA was 94.6% in symptomatic subjects and 93.2% in asymptomatic subjects. Negative percent agreement (NPA) was \>98% in all specimen types.

###### 

Specimen-specific agreement of the Aptima Mycoplasma genitalium assay in urogenital specimens from female and male subjects

  Specimen type and subject symptom status[^*a*^](#T4F1){ref-type="table-fn"}   No. of specimens   Comparison of assay results (no.)   Positive % agreement (95% CI)   Negative % agreement (95% CI)                           
  ----------------------------------------------------------------------------- ------------------ ----------------------------------- ------------------------------- ------------------------------- --- ------------------- -------------------
  Clinician-collected vaginal swab                                                                                                                                                                                             
      Sym                                                                       1,050              123                                 12                              913                             2   98.4 (94.4--99.6)   98.7 (97.7--99.3)
      Asym                                                                      679                52                                  5                               621                             1   98.1 (90.1--99.7)   99.2 (98.1--99.7)
      Overall                                                                   1,729              175                                 17                              1,534                           3   98.3 (95.2--99.4)   98.9 (98.3--99.3)
  Patient-collected vaginal swab                                                                                                                                                                                               
      Sym                                                                       1,047              121                                 18                              908                             0   100 (96.9--100)     98.1 (96.9--98.8)
      Asym                                                                      677                52                                  6                               617                             2   96.3 (87.5--99.0)   99.0 (97.9--99.6)
      Overall                                                                   1,724              173                                 24                              1,525                           2   98.9 (95.9--99.7)   98.5 (97.7--99.0)
  Endocervical swab                                                                                                                                                                                                            
      Sym                                                                       1,057              115                                 4                               935                             3   97.5 (92.8--99.1)   99.6 (98.9--99.8)
      Asym                                                                      677                48                                  3                               624                             2   96.0 (86.5--98.9)   99.5 (98.6--99.8)
      Overall                                                                   1,734              163                                 7                               1,559                           5   97.0 (93.2--98.7)   99.6 (99.1--99.8)
  Female urine                                                                                                                                                                                                                 
      Sym                                                                       1,074              106                                 7                               955                             6   94.6 (88.8--97.5)   99.3 (98.5--99.6)
      Asym                                                                      700                41                                  2                               654                             3   93.2 (81.8--97.7)   99.7 (98.9--99.9)
      Overall                                                                   1,774              147                                 9                               1,609                           9   94.2 (89.4--96.9)   99.4 (98.9--99.7)
  Male urethral swab                                                                                                                                                                                                           
      Sym                                                                       866                102                                 1                               761                             2   98.1 (93.3--99.5)   99.9 (99.3--100)
      Asym                                                                      697                60                                  5                               631                             1   98.4 (91.3--99.7)   99.2 (98.2--99.7)
      Overall                                                                   1,563              162                                 6                               1,392                           3   98.2 (94.8--99.4)   99.6 (99.1--99.8)
  Penile meatal swab                                                                                                                                                                                                           
      Sym                                                                       870                101                                 8                               756                             5   95.3 (89.4--98.0)   99.0 (97.9--99.5)
      Asym                                                                      693                61                                  6                               623                             3   95.3 (87.1--98.4)   99.0 (97.9--99.6)
      Overall                                                                   1,563              162                                 14                              1,379                           8   95.3 (91.0--97.6)   99.0 (98.3--99.4)
  Male urine                                                                                                                                                                                                                   
      Sym                                                                       874                99                                  2                               770                             3   97.1 (91.7--99.0)   99.7 (99.1--99.9)
      Asym                                                                      704                60                                  0                               643                             1   98.4 (91.3--99.7)   100 (99.4--100)
      Overall                                                                   1,578              159                                 2                               1,413                           4   97.5 (93.9--99.0)   99.9 (99.5--100)

Symptom status was determined based on subject-reported symptoms. Asym, asymptomatic; Sym, symptomatic.

[Figure 2](#F2){ref-type="fig"} depicts the distribution of female and male urogenital specimens with unique and shared positive AMG assay results. The majority of subjects were positive for M. genitalium in more than one specimen type (85.7% for female specimens; 77.3% for male specimens). However, for both female and male subjects, a minority of subjects had positive AMG assay results in only one sample type (e.g., 7/193 patient-collected vaginal swab specimens; 28/174 penile meatal swab specimens). Most subjects had positive AMG results for two or more specimen types; 121 (55.8%) females and 138 (68%) males reported positive AMG results in all specimen types assessed.

![Joint distribution of Aptima Mycoplasma genitalium assay positive results in clinical specimens from female (*n* = 217) (A) and male (*n* = 203) (B) subjects. Specimen category values are the number (percent) of test-positive subjects for each specimen type. CVS, clinician-collected vaginal swab; ES, endocervical swab; FU, female urine; MU, male urine; PMS, penile meatal swab; PVS, patient-collected vaginal swab; US, male urethral swab.](JCM.01125-19-f0002){#F2}

Receiver operating characteristic (ROC) curve analysis was performed on the female and male urogenital specimens ([Fig. 3](#F3){ref-type="fig"}). The area under the curve (AUC) estimates ranged from 88.8 for female urine specimens to 98.9 for patient-collected vaginal swab specimens and from 94.5 for male penile meatal swab specimens to 99.4 for male urethral swab specimens.

![ROC curve analysis of female (A) and male (B) clinical specimen types for detection of M. genitalium-infected subjects. CVS, clinician-collected vaginal swab; ES, endocervical swab; FU, female urine; MU, male urine; PMS, penile meatal swab; PVS, patient-collected vaginal swab; US, male urethral swab.](JCM.01125-19-f0003){#F3}

DISCUSSION {#s4}
==========

This study reports the results of a prospective multicenter clinical performance evaluation of the Aptima Mycoplasma genitalium assay for detection of M. genitalium. These results provide clinical efficacy evidence for the first IVD NAAT for M. genitalium detection in the United States. Following completion of this study, the assay received FDA clearance (510k\# DEN180047) for the detection of M. genitalium in patient- and clinician-collected urogenital specimens from symptomatic and asymptomatic subjects, including minors. The FDA clearance will now allow laboratories to test for M. genitalium in a wide variety of urogenital specimens without having to develop and validate laboratory-developed tests ([@B30]) and will allow clinicians to easily detect this pathogen in their patients.

The results of this study are in concert with previous research study results that have highlighted the accuracy of this assay ([@B25], [@B29][@B30][@B32]). The prevalence of M. genitalium observed in this study in symptomatic and asymptomatic persons is consistent with that previously reported for the various types of specimens used for detection in males and females ([@B9], [@B15][@B16][@B17], [@B26], [@B31]). The performance of the assay in multiple specimen types should allow clinicians to choose the specimen type most appropriate for individual patient management. For females, the vaginal swab had the best performance, with self-collected vaginal swabs having higher sensitivity (98.9%) than clinician-collection vaginal swabs (92%). Female urine and endocervical swabs showed somewhat lower sensitivity (81.5% and 77.8%, respectively), consistent with previous reports ([@B25], [@B36]); however, as with the vaginal swab specimens, these two specimen types had positive and negative likelihood ratios significantly different from unity, indicating high probabilities for diagnostic accuracy using these two specimen types. In males, the urethral swab demonstrated high sensitivity of 98.2%, and detection rates of infections using male urine and the self-collected penile-meatal swab were similar, giving clinicians options for sampling male patients. From the ROC analysis, all female and male specimen types had AUC values greater than 88%.

To assess the effect of anatomic site-specific infection on sensitivity and specificity estimates determined using the PIS standard, a comparison of AMG assay and Alt TMA assay results within the same specimen type was performed. Positive percent agreement with the specimen-infected status was \>95% for all specimen types except female urine, for which the PPA was 94.6% in symptomatic subjects and 93.2% in asymptomatic subjects. Negative percent agreement was \>98% for all specimen types. This suggests the somewhat lower diagnostic value (PLR and NLR) and/or diagnostic accuracy (sensitivity and specificity) estimates associated with some specimen types such as female urine may be due to anatomic site-specific infections (e.g., urinary tract-positive/genital tract-negative) rather than specimen matrix effects on assay performance.

While there is little debate that M. genitalium is sexually transmitted, there is wide discrepancy in the prevalence detected in the general population compared to the prevalence in patients seeking care from many types of clinics. In lower-risk populations, an M. genitalium prevalence of approximately 1% to 3% has been reported in both men and women ([@B38], [@B39]). In higher-risk populations attending STI clinics, prevalences of 9% to 24% in men and 11% to 16% in women have been reported ([@B13][@B14][@B16]). The debate is whether asymptomatic infection with M. genitalium is associated with disease and the future development of adverse sequelae. In this AMES study, the prevalences in symptomatic males and females were 12% and 11.6%, respectively, whereas, in asymptomatic persons the prevalences were 8.8% and 7.9%, respectively, demonstrating a prevalence not very different from the prevalence of chlamydia in symptomatic women seen in many health care settings. There are many observational reports that disease manifestations of persistent urethritis ([@B25]), cervicitis ([@B16], [@B17], [@B40][@B41][@B42]), and even pelvic inflammatory disease (PID) and other adverse reproductive sequelae ([@B17], [@B43], [@B44]) are associated with M. genitalium detection in males and females. An unmet need for understanding the public health significance of infection with M. genitalium includes prospective trials that demonstrate that screening and treating asymptomatic persons prevents adverse reproductive sequelae in women and persistent urethritis and sequelae in asymptomatic men although such studies are likely to be costly.

A major concern with the increasing use of diagnostic testing and treatment of infected patients is the high antibiotic resistance of M. genitalium to azithromycin, the first-line antibiotic used to treat urogenital infections ([@B22], [@B23], [@B31], [@B33]). Macrolide resistance rates of greater than 40% are common worldwide and appear to be increasing; this is especially important for the treatment of PID caused by M. genitalium, where standard syndromic treatment may fail ([@B45][@B46][@B48]). It will be important to incorporate antibiotic resistance detection for macrolides and other antibiotic classes into future screening algorithms for M. genitalium as part of the larger antibiotic stewardship efforts needed for the clinical management of all STIs.

Our study has limitations. We did not collect oropharyngeal or rectal specimens, potentially important sources of M. genitalium infection and transmission, and we do not have coinfection data for other STIs. Additionally, there is no information about the antibiotic resistance status of M. genitalium-positive subjects, which is an important clinical consideration ([@B31], [@B46][@B47][@B48]). We also lack extensive history on the sexual orientation of subjects and their sex partners, HIV status, or other risk factors. However, this study was not designed to address those questions.

Strengths of this study include adherence to cGCP regulations to enroll a large, diverse cohort from six geographic areas of the United States, including 15 states and the District of Columbia and representing patients attending multiple clinical practice types. In addition, multiple sample types were collected from each patient, providing clinicians options for patient management. Finally, the composite reference standard used in this study consisted of a consensus result from three validated TMA assays targeting M. genitalium rRNAs, eliminating potential bias due to differences in sensitivities between the investigational test and reference assays ([@B34]).

In summary, we now have an FDA-cleared IVD assay that can be used to detect M. genitalium urogenital infections in men and women using cervical, vaginal, urethral, penile-meatal, and urine specimens. Future research will be required to further define the pathogenicity of M. genitalium, the best treatment algorithms, and its significance when detected in asymptomatic persons.
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